Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 7/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.45 |
| ▸ | MEP1B | Q16820 | 4/20 | 0.44 |
| ▸ | MEP1A | Q16819 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8077477 | 0.88 | CYP1A2 (0.48) | HDAC1BCHEUTS2R | |
| SCHEMBL13025044 | 0.85 | TRPM8 (0.48) | TRPM8MRGPRX4HDAC1GABRA1UTS2R | |
| SCHEMBL13024948 | 0.80 | AOC3 (0.49) | HDAC1BCHEUTS2R | |
| Beta-Naphtoic Acid SCHEMBL28421394 | 0.78 | ACHE (0.58) | MRGPRX4MEP1BLTA4HBCHE | |
| SCHEMBL4407864 | 0.77 | MEP1B (0.65) | MRGPRX4MEP1BMEP1ALTA4HBCHE | |
| SCHEMBL13025049 | 0.74 | HDAC1 (0.49) | HDAC1UTS2R | |
| SCHEMBL17073786 | 0.74 | CYP2D6 (0.44) | BCHEUTS2R | |
| SCHEMBL8080511 | 0.73 | AOC3 (0.54) | HDAC1UTS2R | |
| SCHEMBL14864839 | 0.72 | CYP1A2 (0.53) | BCHE | |
| SCHEMBL8965622 | 0.72 | MEP1B (0.56) | MEP1BMEP1ALTA4HBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009051661-A2 | SUBSTITUTED ARYL ALKYLAMINO-OXY-ANALOGS AND USES THEREOF | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2009-04-23 | — | — | WO | disclosed |